The LBx experts UKE, MUG and UU will look into the pre-analytical, methodological conditions and first identify the best LBx method(s). KI, CNIO, Umeå, UKHD and UKSH are expert centers for pancreatic cancer and will provide both certified data sets of pancreatic cancer patients, premalignant conditions (IPMN) and individuals at risk together with stored blood samples – to be entered into a central repository at CMR who has expertise in integrating different data for further (AI-supported) analysis.
The overall goal of this WP is a plan for a prospective longitudinal study in patients with premalignant conditions of whom only a small proportion will eventually develop pancreatic cancer. In preparation for such a study, we aim to make use of already collected, well-defined archival biobanking from several partners to identify those markers best suited to detect early pancreatic cancer. We have to take into account the different pre-analytical sample procurement methods that will be recorded.